Abbreviations
TKI Tyrosine kinase inhibitors
METC Medical ethical committee
KWF  Dutch Cancer Society
ZonMw The Netherlands Organisation for Health Research and Development
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information
Supplementary information accompanies this paper at 10.1186/s12904-020-00591-4.

We want to thank Lemke Pronk, Svitlana Tarasevych, Marian Tiemessen, Denise de Jong and Verina van Diepen for including the patients for this study.
Many thanks to Nicole Billingy and Philippa Phelp as native English speakers for their help to improve the language of the manuscript.

Authors’ contributions
Conception and design: AM, AB, HRWP, BDOP. Provision of study materials or patients: AB. Collection and assembly of data: AM, AB, HRWP, BDOP, JCMB. Data analysis and interpretation: AM, AB, HRWP, BDOP. Manuscript writing: AM, AB, HRWP, BDOP, JCMB. Final approval of manuscript: AM, AB, HRWP, BDOP, JCMB. All authors have read and approved the manuscript

Funding
This work was funded by the Dutch Cancer Society (KWF) and The Netherlands Organisation for Health Research and Development (ZonMw). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
This study was approved by the medical ethical committee (METc) of the VU University Medical Centre in Amsterdam, the Netherlands (number NL57455.029.16). Both patients and relatives gave written consent to participate in the study.

Consent for publication
Not Applicable.

Competing interests
The author(s) indicated no potential conflicts of interest. There were also no (non-)financial competing interests.